Pembrolizumab superiority shown as first-line in MSI-H mCRC

The first phase 3 study of pembrolizumab versus standard-of-care demonstrated superiority for first-line pembrolizumab in patients with high microsatellite instability (MSI-H) metastatic colorectal cancer.

The first phase 3 study of pembrolizumab versus standard-of-care (i.e. chemotherapy + bevacizumab or cetuximab) demonstrated superiority for first-line pembrolizumab in patients with high microsatellite instability (MSI-H) metastatic colorectal cancer (mCRC), Prof. Thierry André (St Antoine Hospital, France) reported [1].

About 5% of all mCRC are characterized by MSI-H, often linked with germline mutations in Lynch Syndrome (also known as hereditary non-polyposis colorectal cancer or HNPCC). Mismatch repair status and MSI-H predict the clinical benefit of immune checkpoint blockade with pembrolizumab as first-line therapy for MSI-H mCRC and has been FDA-approved for adults and children with metastatic tumors with MSI, regardless of the tumor type. Previously, KEYNOTE-164 evaluated the anti-tumor activity of pembrolizumab in previously treated, metastatic, microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) colorectal cancer (CRC) [2]. In the current study, treatment-naïve MSI-H patients were treated with first-line pembrolizumab.

KEYNOTE-177 studied 307 stage IV treatment-naïve CRC patients with confirmed MSI-H/dMMR with good performance status. Patients were randomized to either pembrolizumab (n=153; 200 mg Q3W for up to 35 cycles) or investigator-choice chemotherapy (n=154; mostly mFOLFOX6- or FOLFIRI-based, plus bevacizumab or cetuximab). There was an optional crossover to the pembrolizumab regimen for patients with centrally verified disease progression by RECIST v1.1. The dual primary endpoints were progression-free survival (PFS) per RESIST v1.1 by blinded independent central review (BICR) and overall survival. Secondary endpoints were overall response rate and safety. Tumour response was assessed at week 9 and Q9W thereafter per RESIST cv1.1 by BICR.

With a median follow-up of 32.4 months (range 24.0-48.3), pembrolizumab was superior to chemotherapy in terms of PFS: 16.5 months in the pembrolizumab group versus 8.2 months in the chemotherapy control arm (HR 0.60; 95% CI 0.45-0.80; P=0.0002). Overall survival data are still immature. The overall response rate was 43.8% in the pembrolizumab arm as compared with 33.1% in the chemotherapy control arm (P=0.0275). The median duration of response was not reached in the pembrolizumab arm but was 10.6 months in the chemotherapy arm.

Treatment-related adverse events of grade 3 or higher were reported in 22% of the patients in the pembrolizumab arm, as opposed to 66% of the patients in the chemotherapy arm. No new toxicities with pembrolizumab were observed.

In short, pembrolizumab provided a clinically meaningful and statistically significant improvement in PFS versus chemotherapy in patients with MSI-H mCRC. Responses were also more durable with pembrolizumab. Furthermore, there was an improved safety profile with pembrolizumab versus chemotherapy. Prof. André concluded that “pembrolizumab should be considered ta new standard-of-care as first-line therapy in patients with MSI-H mCRC.”

References:
1. André T, et al. Phase III Keynote-177 trial comparing pembrolizumab to standard therapy as first-line treatment for select patients with advanced colorectal cancer. ASCO Virtual Meeting, 29-31 May 2020, Abstract LBA4.
2. Le DT, et al. Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: KEYNOTE-164. J Clin Oncol. 2020;38(1):11‐19.

Esanum is an online network for approved doctors

Esanum is the medical platform on the Internet. Here, doctors have the opportunity to get in touch with a multitude of colleagues and to share interdisciplinary experiences. Discussions include both cases and observations from practice, as well as news and developments from everyday medical practice.

Esanum ist ein Online-Netzwerk für approbierte Ärzte

Esanum ist die Ärzteplattform im Internet. Hier haben Ärzte die Möglichkeit, mit einer Vielzahl von Kollegen in Kontakt zu treten und interdisziplinär Erfahrungen auszutauschen. Diskussionen umfassen sowohl Fälle und Beobachtungen aus der Praxis, als auch Neuigkeiten und Entwicklungen aus dem medizinischen Alltag.

Esanum est un réseau en ligne pour les médecins agréés

Esanum est un réseau social pour les médecins. Rejoignez la communauté et partagez votre expérience avec vos confrères. Actualités santé, comptes-rendus d'études scientifiques et congrès médicaux : retrouvez toute l'actualité de votre spécialité médicale sur esanum.